乳房切除术后对重建乳房放疗后重建失败与主要并发症的相关因素
本研究基于2000至2017年前瞻性收集的机构数据库,纳入206侧重建乳房(202例患者),比较调强放疗(IMRT)139侧与常规放疗(CRT)67侧的重建结局。IMRT组重建失败率3.0%对CRT组16.4%(P=0.002),主要并发症率6.8%对24.6%(P<0.001);CRT与植入物失败(HR 5.54,P=0.003)及并发症增加(HR 3.83,P=0.001)显著相关,多因素分析后仍显著。两组2年总生存(P=0.12)与局部复发(P=0.41)无差异。
要点
- IMRT组重建失败率3.0%,CRT组16.4%(P=0.002)。
- IMRT组主要并发症率6.8%,CRT组24.6%(P<0.001)。
- CRT与植入物失败(HR 5.54,P=0.003)及并发症增加(HR 3.83,P=0.001)显著相关。
核心结论
- 使用IMRT可能较CRT改善重建结局,显著降低重建失败率与并发症率,且不损害局部控制或生存。
研究设计与样本
- 前瞻性收集的机构数据库查询,纳入2000至2017年接受乳房切除术、即刻植入物或自体组织重建、并于术后1年内对重建乳房放疗的至多IIIC期乳腺癌患者。
- 共206侧重建乳房(202例患者),IMRT组139侧,CRT组67侧;中位随访45个月(范围4-210个月)。
- 8例患者因随访不足(<2年)被排除在毒性分析之外。
主要发现
- IMRT组重建失败率3.0%,CRT组16.4%(P=0.002);IMRT组主要并发症率6.8%,CRT组24.6%(P<0.001)。
- 单因素分析中CRT显著预测植入物失败(HR 5.54,P=0.003)及并发症增加(HR 3.83,P=0.001),多因素分析后仍显著。
- 两组2年总生存(P=0.12)与局部复发(P=0.41)无差异。
关键数值与推荐
- 重建失败定义为需手术修整或取出植入物的并发症。
- 其他主要并发症定义为任何感染、挛缩、坏死或纤维化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Postmastectomy radiation therapy is known to increase risk of complications in the reconstruction setting. We aim to identify the variables associated with reconstruction failure and other major complications. METHODS AND MATERIALS: A prospectively collected institutional database was queried for patients with up to stage IIIC breast cancer treated from 2000 to 2017, undergoing mastectomy, immediate implant or autologous tissue reconstruction, and radiation to the reconstructed breast within 1 year of surgery. Reconstruction failure was defined as complication requiring surgical revision or implant removal. Additional major complications were defined as any infection, contracture, necrosis, or fibrosis. Covariates of interest included age, body mass index, smoking status, stage, hormone receptor and HER2 status, systemic therapy timing, radiation technique, nodal irradiation, and interval between surgery and start of postmastectomy radiation therapy. Differences in complication rates were assessed with χ² or Fisher exact tests. Competing risk regression was used to estimate hazard ratios; covariates were included one at a time to avoid over adjustment. RESULTS: A total of 206 reconstructed breasts in 202 patients resulted from our initial query, with 139 treated with intensity-modulated radiation therapy (IMRT) and 67 treated with conventional radiation therapy (CRT). Median follow-up was 45 months (range, 4-210 months); patient cohorts were generally similar. Eight patients were excluded from toxicity analysis for insufficient follow-up (<2 years). Overall, reconstruction failure and major complication rates were significantly lower in the IMRT group. Reconstruction failure rates were 3.0% for IMRT versus 16.4% for CRT (P = .002), and major complication rates were 6.8% for IMRT versus 24.6% for CRT (P < .001). On univariate analysis, CRT was significantly predictive of implant failure (hazard ratio, 5.54; P = .003) and increased complication rates (hazard ratio, 3.83; P = .001). Significance persisted on multivariable analysis. Survival outcomes were similar, with no difference in 2 year overall survival (P = .12) and local recurrence (P = .41). CONCLUSIONS: Using IMRT may improve reconstruction outcomes over CRT, with significantly lower reconstruction failure and complication rates without compromising local control or survival.
引用
- Lee CT, Ruth K, Patel S, et al. Factors Associated with Reconstruction Failure and Major Complications After Postmastectomy Radiation to a Reconstructed Breast. Pract Radiat Oncol. 2022. PMID: 36332800. doi:10.1016/j.prro.2022.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。